Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Leitner, M.
Advances in T-cell Therapy for Cancer Patients.
Humanmedizin; [ Diplomarbeit ] Graz Medical University; 2020. pp. 167
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Heinemann Akos
- Kargl Julia
- Altmetrics:
- Abstract:
- This diploma thesis with the title "Advances in T-cell Therapy for Cancer Patients" deals with the topic of T-cell therapy in oncology. Therefore, basics of cancer development, the immune system and the possibilities in cancer therapy were investigated. The focus of this thesis is a systematic review of T-cell therapy, including latest developments and current studies. The method used for this work is a systematic literature review. The literature research includes books, various publications from journals and current treatment guidelines. Therefore, PubMed and ClinicalTrials.gov were selected as databases. Wherever possible, current literature was used, in particular in the chapters of the different forms of T-cell therapies. The results include a systemic analysis of the different forms of T-cell therapy in various tumor entities. The possibilities of tumor therapies are discussed and a short excursion into the history of T-cell therapy is given. Results from pre-clinical and clinical studies using T-cell therapies in treatment of different forms of cancer are discussed. In addition, side effects and limitations for each form of T-cell therapy are shown. The manufacturing process of T-cell therapy products is described as well. The influence of various factors, such as the tumor microenvironment or the properties of the used T-cells, are explored. Future perspectives of T-cell therapy in form of new approaches, which might enable a widespread use, are presented. Results of T-cell therapy are compared to results of standard cancer therapies, such as chemotherapy or radiation therapy. Possible combinations of T-cell therapies with other forms of cancer treatments and their results in clinical studies are shown. Already approved T-cell therapies are presented and current ongoing clinical trials are described. Due to advances in immunotherapy research, T-cell therapies have already successfully induced tumor regression or even cure in patients in clinical studies. With the approval of CAR T-cell therapies, they are already part of cancer treatments for patients with various hematologic malignancies. Continued research in the field of T-cell therapy will make it available for many cancer patients in the future.